Philips Medical Systems Nederland B.V.

Veenpluis 6, 5684 PC Best, Netherlands; High Tech Campus 52, 5656 AG Eindhoven, Netherlands All Netherlands companies → — Founded 1987

Clinical AI Platform Healthcare Conglomerate Medical Device / Hardware

Nuclear Medicine Oncology Radiology

Oncology AI Radiology & Imaging AI

Not applicable (subsidiary of a publicly traded company) — Not applicable (subsidiary of a publicly traded company)

Claim this company

Products

Vereos PET/CT

Philips Medical Systems Nederland B.V.

Oncology AI

The Philips Vereos PET/CT is the world's first fully digital PET/CT system, utilizing proprietary Digital Photon Counting (DPC) technology for superior image quality, enhanced small lesion detectability, and improved quantitative accuracy. It incorporates AI-powered Adaptive Reconstruction and offers faster scans with reduced radiation dose.

Contact vendor for pricing

See all 1 product →

About Philips Medical Systems Nederland B.V.

Philips Medical Systems Nederland B.V. operates as a key entity within Royal Philips, a global leader in health technology dedicated to improving people’s health and well-being across the entire health continuum. For physicians, this translates into a comprehensive suite of advanced technology and integrated solutions designed to enhance diagnostic precision, optimize treatment pathways, and streamline patient care. The company’s offerings span diagnostic imaging, including MRI, CT, ultrasound, and X-ray systems, as well as sophisticated image-guided therapy solutions, patient monitoring, and health informatics platforms.

A significant focus for Philips, and by extension Philips Medical Systems Nederland B.V., is the integration of Artificial Intelligence (AI) and Machine Learning (ML) into healthcare. These AI-enabled solutions are engineered to address critical challenges faced by healthcare professionals, such as staff shortages, administrative burdens, and the increasing demand for care. By providing clinical insights, automating repetitive tasks, and optimizing workflows, Philips’ AI aims to empower clinicians to make more informed decisions, deliver personalized treatment, and expand the reach of high-quality care from hospitals to homes. This includes advancements in areas like cardiovascular ultrasound analysis, AI-powered MRI for faster imaging, and intelligent software for improved radiology workflows, all contributing to a vision of more efficient, effective, and patient-centric healthcare.

Focus Areas

Radiology Cardiology Pathology Ultrasound Image-Guided Therapy Patient Monitoring Enterprise Informatics Workflow Optimization Precision Diagnosis Personalized Treatment Home Healthcare Sleep and Respiratory Care

Business Intelligence

Key Investors	Exor N.V., BlackRock, Vanguard Group (major institutional investors in Royal Philips)
Partnerships	Ibex Medical Analytics (AI-enabled pathology), Edwards Lifesciences (AI-powered mitral valve repair), Amazon Web Services (HealthSuite cloud platform), Anumana (ECG AI Marketplace)
Acquisitions	SpectraWAVE (AI-powered intravascular imaging), Cardiologs (AI-powered cardiac diagnostics)
Technology	Philips HealthSuite platform (cloud-based Platform-as-a-Service leveraging AWS for imaging AI and machine learning, supports cloud-native, edge computing, and AI operating system approaches for data integration and dynamic workflows)
FDA Clearances	Multiple (including AI-enabled CT system, AI-powered DeviceGuide for mitral valve repair, AI-powered SmartHeart for cardiac MR planning, and was the first to receive FDA clearance for a digital pathology scanner in 2017) cleared products (estimated)

At a glance

Founded 1987

HQ Veenpluis 6, 5684 PC Best, Netherlands; High Tech Campus 52, 5656 AG Eindhoven, Netherlands · Netherlands

Team size 10001+ (for PHILIPS Medical Systems Netherlands - B.V. Philips Healthcare (HQ))

CEO Roy Jakobs (CEO of Royal Philips, the parent company)

Funding Not applicable (subsidiary of a publicly traded company) — Not applicable (subsidiary of a publicly traded company)

FDA clearances Multiple (including AI-enabled CT system, AI-powered DeviceGuide for mitral valve repair, AI-powered SmartHeart for cardiac MR planning, and was the first to receive FDA clearance for a digital pathology scanner in 2017) (estimated)

Products 1

Products by Philips Medical Systems Nederland B.V.

1 product in the directory

Vereos PET/CT

Philips Medical Systems Nederland B.V.

Oncology AI

Contact vendor for pricing

What the Web Says

Philips Medical Systems Nederland B.V. is a key player in the healthcare technology industry, specializing in medical imaging, diagnostic, and patient monitoring solutions. The company is part of Royal Philips, which has a strong focus on health technology and innovation. Reviews indicate a mixed sentiment regarding both its products and its environment as an employer.

Overall: Mixed

Strengths

Products like Advanced Visualization Workspace 15 and IntelliSpace PACS are praised for their quality in reconstructions, accurate filtering, and comprehensive analysis tools.
Philips' medical systems are noted for enhancing diagnostic confidence and streamlining reporting through optimized workflows and automated results.
The company is recognized for its strong innovation in health technology and high ranking in patent applications.
Some employees appreciate the rewarding work, good work-life balance, and supportive colleagues.
Philips Medical Systems is considered a good employer in the Netherlands with competitive pay and benefits.
The Philips HealthSuite Digital Platform is seen as a useful tool for patients and hospitals, compiling and analyzing clinical data to provide more effective and qualitative healthcare services.

Limitations

Some employees report issues with management, citing a lack of care for individuals, poor job security, and a blame culture.
There are concerns about frequent layoffs and an ever-changing environment and leadership leading to stress.
The company is criticized for being disconnected from upper management and having a highly politicized and passive-aggressive culture.
Some Reddit users express a decline in trust in the Philips brand for consumer electronics, noting that many products are now licensed to other companies.
Philips sets fixed requirements for support (e.g., patch levels for servers) which can be difficult to integrate into broader enterprise patching strategies.
Philips Medical Systems Nederland B.V. has been subject to a significant number of FDA recalls.

Based on reviews from: G2, Glassdoor, Capterra, Zippia, Payscale, Indeed.com, Reddit, HosmartAI, Trustpilot, Laboratorium.nl, Argus HQ, Gartner Peer Insights, Creditsafe

Last updated: 2026-07-18

Videos

News, demos, and interviews about Philips Medical Systems Nederland B.V..

Loading videos...

Videos load interactively. If none appear, search YouTube for Philips Medical Systems Nederland B.V. →

View all on YouTube

Press & Coverage

BfArM

Urgent Field Safety Notice for Philips Allura system by Philips Medical Systems Nederland B.V.

BfArM issued an Urgent Field Safety Notice regarding the Philips Allura system by Philips Medical Systems Nederland B.V. on July 14, 2026, concerning radiological equipment for vascular diagnostics.

2026-07

BfArM

Urgent Field Safety Notice for Philips Allura and Azurion by Philips Medical Systems Nederland B.V.

An Urgent Field Safety Notice was released by BfArM on July 6, 2026, for Philips Allura and Azurion systems from Philips Medical Systems Nederland B.V., related to radiological equipment for vascular diagnostics.

2026-07

DOTmed

FDA recalls some Philips Integris-Allura fluoroscopy systems

The FDA announced a recall of certain Philips Integris-Allura fluoroscopy systems, initiated by Philips Medical Systems Nederland B.V. on April 28, 2026, due to potential oil leakage in the X-ray tube cooling units.

2026-06

accessdata.fda.gov

Class 2 Device Recall Philips Azurion

Philips Medical Systems Nederland B.V. issued a Class 2 Device Recall for Philips Azurion systems due to a software design issue that may cause a dark, clinically unusable image after a pedal tap during Roadmap Pro.

2026-06

Cleary Gottlieb

Philips Secures Dismissal of Abuse of Dominance Proceedings

Cleary Gottlieb successfully represented Philips Medical Systems Nederland B.V. and other Philips entities in obtaining the dismissal of abuse of dominance proceedings before the Italian Competition Authority concerning the maintenance market for high-tech diagnostic imaging devices.

2021-05

Innovative Health Initiative (IHI)

IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments

The Philips-coordinated IMAGIO consortium, including Philips Medical Systems Nederland B.V., was awarded a EUR 24 million Innovative Health Initiative (IHI) grant to research less invasive cancer treatments for lung cancer, liver cancer, and soft tissue sarcomas.

2023-06

PubMed (PLoS One)

A handheld fiber-optic tissue sensing device for spine surgery

Researchers, including those from Philips Medical Systems Nederland B.V., developed a handheld fiber-optic tissue sensing device for real-time bone tissue differentiation during spine surgery using Diffuse Reflectance Spectroscopy.

2024-12

ihi-improve.eu

IMPROVE Project Hosts 3rd Stakeholders' Community Workshop to Advance Value-Based Healthcare in Europe

The IHI-funded IMPROVE project, with a workshop organized by Philips Medical Systems Nederland BV, will host its 3rd Stakeholders' Community Workshop in February 2026 to advance Value-Based Healthcare in Europe through patient-generated health data.

2026-02

Frequently Asked Questions

What are Philips Medical Systems Nederland B.V.'s latest innovations and product offerings across radiology, cardiology, and pathology, particularly in precision diagnosis and personalized treatment?

Philips offers cutting-edge diagnostic imaging, enterprise informatics, and AI-integrated solutions across radiology, including the new AI-powered detector-based spectral CT, Verida, for enhanced diagnostic precision. In cardiology, they provide integrated solutions combining imaging, devices, software, and services for interventional procedures and advanced multimodality cardiac imaging. For pathology, Philips is a leader in digital pathology, leveraging clinical informatics and data management, and collaborates on AI solutions to accelerate diagnosis.

How does Philips Medical Systems Nederland B.V. ensure compliance with global healthcare regulations and data security standards (e.g., GDPR, HIPAA) for its enterprise informatics and patient monitoring solutions?

Philips maintains a robust compliance program with documented policies, executive oversight, and cross-functional accountability, adhering to regulatory standards like GDPR and HIPAA. They implement measures such as data de-identification, encryption, role-based access control, secure development lifecycles, and mandatory data breach reporting. Their enterprise-wide cybersecurity strategy for patient monitoring includes assessments, software maintenance, and remote support to protect data confidentiality, integrity, and availability.

What support and service models does Philips Medical Systems Nederland B.V. offer to optimize workflow and ensure uptime for its image-guided therapy and ultrasound systems?

Philips provides comprehensive customer service solutions, including technical support and product documentation, to ensure optimal performance. For image-guided therapy and ultrasound systems, they offer 'Technology Maximizer,' an upgrade service that enhances clinical capabilities, performance, and security while providing predictable budgeting. Their systems, like the Azurion platform, are designed with intuitive interfaces to streamline workflows, reduce procedure times, and improve lab efficiency.

Can you describe Philips Medical Systems Nederland B.V.'s approach to partnerships and integration capabilities with other healthcare IT systems to enhance enterprise informatics and data interoperability?

Philips is actively involved in developing and advancing industry standards for healthcare IT interoperability, such as IHE, HL7, FHIR, and DICOM. They employ an enterprise-wide approach to facilitate seamless patient data exchange across diverse care settings and multi-vendor environments, aiming to improve clinical workflows. The Philips HealthSuite Interoperability platform is a cloud-enabled solution designed to connect third-party systems and enable smooth data workflows across the imaging enterprise.

What solutions does Philips Medical Systems Nederland B.V. provide for home healthcare and sleep and respiratory care, and how do they integrate with hospital-based systems?

Philips offers a wide array of solutions for sleep and respiratory care, including CPAP machines, masks, home ventilation devices, and patient management software. Their strategy emphasizes connecting extended care teams seamlessly and managing patient data across the health continuum, supporting chronic care at home. It's important to note Philips is actively addressing a June 2021 recall concerning certain sleep and respiratory care devices.

How does Philips Medical Systems Nederland B.V. address the total cost of ownership and pricing models for its advanced medical imaging and patient monitoring equipment?

Philips recognizes that the purchase price is only a portion of the total cost of ownership (TCO) for medical equipment, which includes maintenance, upgrades, and training. To address this, they offer subscription models like 'Technology as a Service' (TaaS) and 'Enterprise Monitoring as a Service' (EMaaS). These models provide predictable costs for ongoing maintenance, upgrades, and security, aiming to alleviate the burden of technology management for healthcare institutions.

What is the current strategic direction and financial stability of Philips Medical Systems Nederland B.V., and how does this impact long-term product support and innovation?

Philips' strategic direction focuses on being a leading health technology company, driving innovation through platform-based solutions that integrate hardware, software, data, and AI. They prioritize quality and compliance, investing significantly in R&D (approximately 9% of sales in 2024) to ensure long-term product support and continuous innovation. Their recent Capital Markets Day in February 2026 outlined their 2026-2028 plan, demonstrating a commitment to sustainable value and strategic growth.

Related Companies

Suggest an Edit →